17 - 19 November 2021

Program

The MedTech21 Annual Conference will feature international and local presenters speaking on the key issues affecting MedTech. The program is subject to changes.

Welcome to MedTech21

Day 1
11:00-11:30
Ian-Burgess.jpg

Ian Burgess

Chief Executive Officer
Medical Technology Association of Australia

Panel Discussion: How Industry Can Best Engage With Government

Day 1
11:30-12:15
As Australia begins to emerge from the COVID-19 pandemic, and with the next Federal Election on the horizon, the MedTech community faces a dynamic political operating environment that presents both challenges and opportunities. To share their insights on what MedTech companies can expect and how best to engage with Government, MTAA will be hosting a special PulseLine Political Panel discussion with three of the Parliament’s rising stars, Dr Katie Allen MP (LIB) and Mr Milton Dick MP (ALP) and Senator Perin Davey (NATS).

Session Sponsor

Dick-M

Mr Milton Dick MP

Federal Member for Oxley (QLD)
Australian Labor Party
Katie-Allen

Dr Katie Allen MP

Federal Member for Higgins (VIC)
Liberal Party of Australia
1565311946610

Senator Perin Davey

Senator for New South Wales (NATS)
The Nationals
Matt-Versi

Matthew Versi

Senior Manager, Public Affairs & Advocacy
Medical Technology Association of Australia

Panel Discussion: Reform Overview & Update

Day 1
12:15-13:00
Brief overview of the main government goals and pillars of reform; a general update on progress of key issues and timelines for future consultation and implementation; overview of the approach to legislating change; critical success factors; device industry view of progress and outstanding issues.
Penny

Penny Shakespeare

Deputy Secretary
Department of Health
Paul-Dale-headshot-1

Paul Dale

Director, Policy
Medical Technology Association of Australia
Ian-Burgess.jpg

Ian Burgess

Chief Executive Officer
Medical Technology Association of Australia

Panel Discussion: Benefit Review Methodology & Implementation

Day 1
13:00-13:45
Update on IHPA’s recommendation on methodology; next steps for IHPA and the Department on benefit review; approach to benefit calculations by group; private adjustment approach and relationship to phasing; benefit vs price under PL reform.
James Downie

James Downie

Chief Executive Officer
Independent Hospital Pricing Authority
Elizabeth

Elizabeth Flynn

Assistant Secretary, Prostheses List Reform Taskforce
Department of Health
Fraser Cleave

Fraser Cleave

Director, Sales Operations
Lifehealthcare
Paul-Dale-headshot-1

Paul Dale

Director, Policy
Medical Technology Association of Australia

Panel Discussion: Protheses List Scope & Removals

Day 1
13:45-14:30
Department update on progress of proposed scope and removals including clinical review process; rationale for any removals from 1 Feb 2022; status of negotiations between hospitals and insurers; legislative approach to PL scope; implications for listings and applications; discussion of specific cases.
S Graves (002)

Prof. Stephen Graves

Director
Australian Orthopaedic Association National Joint Replacement Registry
Elizabeth

Elizabeth Flynn

Assistant Secretary, Prostheses List Reform Taskforce
Department of Health
Ben-Harris

Ben Harris

Director Policy and Research
Private Healthcare Australia
lucy_cheetham

Lucy Cheetham

Director Policy and Research
Australian Private Hospital Association
Jo Root

Jo Root

Policy Director
Consumer Health Forum
georgia_psarros_baxter_healthcare_heat_shot

Georgia Psarros

Health Economics Manager
Baxter Healthcare

Afternoon Tea Break
14:30-15:00

Panel Discussion: Prostheses Listings Processes

Day 1
15:00-15:45
Department update on goals and progress (and content of Department paper, if released); listing issues and major solutions – Department and industry perspectives; Abbreviated Pathway; making HTA work for medical devices; cost recovery plans.

Julianne Brettarg

Prostheses List Reform Taskforce
Department of Health
Nicole Barnett

Nicole Barnett

Health Economics Market Access Leader, HEMA, ANZ
Johnson & Johnson Medical
Michael Simmonds

Michael Simmonds

Director ANZ, Health Economics & Government Affairs
Boston Scientific

Panel Discussion: Administration, Utilisation and Compliance

Day 1
15:45-16:30
Department update on goals and progress in managing the PL more effectively; utilisation issues and potential solutions that still prioritise clinician choice; improving transparency and confidence in the PL; simplifying administration while maintaining functionality; role and limits of legislation and regulation.
S Graves (002)

Prof. Stephen Graves

Director
Australian Orthopaedic Association National Joint Replacement Registry
Ben-Harris

Ben Harris

Director Policy and Research
Private Healthcare Australia
Penny

Penny Parish

Director, Prostheses List Reform Taskforce
Department of Health
Robert

Robert Herkes

Chief Medical Officer
Ramsay Health Care
Jo Root

Jo Root

Policy Manager
Consumer Health Forum
Doug Symonds

Doug Symonds

Private Reimbursement Manager
Medtronic

Panel Discussion: Wrap Up

Day 1
16:30-17:00
Panel discussion on the key points of the day
Paul-Dale-headshot-1

Paul Dale

Director, Policy
Medical Technology Association of Australia

Thursday, 18 November 2021

Day 2

Panel Discussion: The Role of the Patient Voice in Health Technology Assessment

Day 2 | 11:15-12:00
In Eric Topol’s book “The Patient Will See You Now” he highlights how the traditional patient doctor relationship is changing in our data driven world. Yet the Health Technology Assessment (HTA) bodies that assess new innovations are slow to adapt to this new world. As patients take control of their own health journey, we are seeing medical device companies looking at how they can include alternative data beyond randomised controlled trials with HTA bodies, including incorporating the voice of patients. The experience of many HTA bodies has been to focus on the uncertainty of a new technology, to raise doubts, and, from an industry perspective, delay approval. How do patients see our HTA system? Do bodies like MSAC truly understand patients’ perspectives of their conditions and how do they measure patient insights in their deliberations? Some HTA systems are exploring a range of innovative strategies to evaluate patient perspectives - what are some of those approaches and how realistic are they in the Australian context?
Sally Wortley

Sally Wortley

Lead, Consumer Evidence and Engagement Unit
Australian Department of Health
J-Bean-web-shot-e1567585562323

Jessica Bean

Chair
Patient Voice Initiative & Cystic Fibrosis
1517000330879

Tanya Hall

Chief Executive Officer
hearts4heart
Todd

Todd Stephenson

Director, Patient Engagement and Experience
Janssen ANZ
Polo Guilbert-Wright Headshot

Polo Guilbert-Wright

Director Of Government Affairs ANZ
Edwards Lifesciences

Interview with Adj. Prof. John Skerritt - TGA

Day 2 | 12:00-12:45 (Concurrent)
MTAA will sit down with Adj Prof John Skerritt, Department of Health, to discuss the changing landscape of medical devices regulations in Australia. This 45 minute session will cover the TGA action plan and numerous regulations changes and reforms that have recently occurred, including the acceptance of EU Conformity Assessment certificates for high-risk devices. There will also be a discussion on Software as a Medical Device (SaMD), Personalised Medical Devices, the future of AI in the health sector, use of real world evidence and the priority review pathway.
john skerritt

Adj Prof John Skerritt

Deputy Secretary, Health Products Regulation Group
Department of Health
jas-profile

Dr Jasjit Baveja

Senior Manager, Regulatory Affairs, Ph.D.
Medical Technology Association of Australia

Panel Discussion: How to Leverage Media to Articulate your Message

Day 2 | 12:00-12:45 (Concurrent)
How to effectively articulate your objectives to the media and ensure that your messages are being heard. How grassroots issues campaigns can be influential in bringing about better outcomes for patients. The more things change, the more they stay the same – two years on. Amplification through digital/social media and getting the balance right between paid, owned and earned media channels.
Paul Cross

Paul Cross

Founder & Publisher
Health Dispatch
Rachle Chun

Rachel Clun

Journalist
The Sydney Morning Herald
Rozalina S Health Industry Hub

Rozalina Sarkezians

Managing Director
Health Industry Hub
rachel-fry-profile

Rachel Fry

Government Relations & Communications Manager
Medical Technology of Association

Adding more EQ and IQ in Healthcare Services using Digital Health

Day 2 | 12:45-13:30 Day 2 | 12:45-13:30 (Concurrent)

Session Sponsor

Tim Spicer

Dr Tim Spicer

Director of Nephrology
Southwest Sydney Health District
Len

Len Usvyat PhD

Vice President, Applied Data Science, Biostatistics, and Epidemiology
Fresenius Medical Care
1615420472951

Dr Milind Nikam

VP - Global Clinical Affairs, Medical Affairs, FMC Asia-Pacific
Fresenius Medical Care
Tansy Michael

Tansy Michael

Business Manager PD ANZ and HD WA
Fresenius Medical Care

Bringing Clinical Trials to Australia

Day 2 | 12:45-13:30 (Concurrent)

Hear about the importance of having clinical trials in Australia from a site, sponsor and academic prospective.

Natascha Millard

Natascha Millard

Stryker
Director_CancerMedicine_ProfJohnZalcberg_OAM-460x250

Prof John Zalcberg OAM

ACTA Board Director
Australian Clinical Trials Alliance
Nicole

Nicola Chapman

Head of Clinical Operations
Macquarie University
Christy Thiel

Christy Thiel

Director Clinical Affairs APAC
Edwards Lifesciences

Panel Discussion: Value-Based Procurement

Day 2 | 13:30-14:15 (Concurrent)
Richard Charter

Richard Charter

Vice President, MedTech Market Access
Alira Health
Will Monoghan

Will Monoghan

Acting Deputy Chief Executive
Northern Territory Health
Paula Williams

Paula Williams

Corporate Accounts Manager
Johnson & Johnson

Med Ed One: Evolution and Revolution

Day 2 | 13:30-14:15 (Concurrent)
We adapted last year at a rapid pace, hosting rudimentary online meetings with existing platforms. Fast forward 18 months - we are integrating high tech teaching tools into ongoing global strategies and technology, building online communities and connecting key opinion leaders across the globe. What will this mean for the future of HCP training? In this session, experts share what they learnt in 2020, what they will keep doing and what they definitely won’t.

Session Sponsor

dr-fristch-img-new

Dr Brett Fritsch

Orthopaedic Surgeon, Knee Specialist
Justin

Dr Justin Barad

Orthopaedic Surgeon, Founder/CEO
Osso VR USA
Nish headshot

Dr Nishanth Krishnananthan

Co-CEO
Vantari VR
Goldenstein

Alex Goldenstein

Regional Sales Manager - NSW/ACT Trauma & Extremities
Stryker

Afternoon Tea Break
14:15-14:45

Around the World on Regulatory

Day 2 | 14:45-15:30 (Concurrent)
In this session, we will be taking a trip around the world, where we will be hearing from experts from New Zealand, the APAC Region and the IMDRF. With the proposed Therapeutic Products Bill continues advanced with a draft legislation being developed, taking into account the consultation process that Ministry of Health (MOH) undertook early 2019. While the process to introduce a new regulatory scheme for New Zealand was stalled while MOH refocused on COVID-19 response, the work is now gathering momentum again. What does the APAC evolving regulatory landscape look like? What are the challenges and opportunities? Hear the strides being made in the AI and software space.
Fiona

Fiona Ryan

Manager Therapeutics, System Strategy & Policy
Ministry of Health New Zealand
Tracey-Duffy

Tracey Duffy

First Assistant Secretary
Department of Health
Miang_Tanakasemsub

Miang Tanakasemsub

Head of QA Commercial & Regulatory Affairs
Cardinal Health
Sue

Sue Hunter

Regulatory Affairs Director ANZ
Abbott Medical

Med Ed Two: The Business of Compliance

Day 2 | 14:45-15:30 (Concurrent)
Join Angell Zhang, Hogan Lovells, William Foster, Johnson & Johnson and Charlotte Hart, Nevro for a thought-provoking discussion on the recent changes to professional development training and where its future could be. Our panellists of educators and legal associates will cover the following:
  • Is face-to-face training still the best format to provide quality education for Healthcare Professionals?
  • Does virtual training provide an equivalent level of education that can be measured?
  • What are the legal ramifications if Industry continues with a virtual or hybrid training format?
  • Should Industry still have a place in the training curriculum?
Zhang_Angell_L89114

Angell Zhang

Senior Associate
Hogan Lovells
Will Foster

Will Foster

Senior Director Education Solutions Asia Pacific
Johnson & Johnson
Charlotte Hart Headshot

Charlotte Hart

Senior Manager, International Professional Education
Nevro

The Crucial Next Steps for End-to-End Connectivity

Day 2 | 15:30-16:15 (Concurrent)
Hear from subject matter experts discussing key statistics, economic challenges that Australia is facing, and the opportunities available to Australia.

Session Sponsor

Alessandra Doolan

Dr Alessandra Doolan

Principal
The Health and Technology Advisory Group (HTAG)
Dr Bryan Tan Head Shot

Dr Bryan Tan

Director APAC Healthcare and Life Sciences
Salesforce
rob-grenfell

Dr Rob Grenfell

Special Advisor Health
CSIRO Future Industries

The Benefits of Workplace Diversity

Day 2 | 15:30-16:15 (Concurrent)
With people living healthier and longer, the need to keep work has never been stronger. What are the benefits and challenges employers are faced with hiring a mature person.

Join this panel of experts where they will discuss the importance of having a diverse workplace and what are the benefits.
Jane Crowe

Jane Crowe

Managing Director ANZ
Cardinal Health
Screen Shot 2021-11-04 at 12.57.17 pm

Yolanda Mallouhi

HR Director, ANZ
Edwards Lifesciences
Screen Shot 2021-11-04 at 1.00.01 pm

Deb Houston

Founder/CEO
iRecruiter Tutor
Elizabeth Pettit

Elizabeth Pettit

Managing Director
Pettit Pharma & Device Search

MedTech Europe Update

Day 2
16:15-17:00
diane

Diana Kanecka

Senior Manager International Affairs
MedTech Europe
George

George Faithfull

Director
George Faithfull Advisory

Friday, 19 November 2021

Day 3

FDA update on US Medical Devices

Day 3
09:00-09:45
This session will provide an update from the FDA regarding the Agency’s focus over the last year in relation to medical device regulation. Topics include the COVID-19 response and lessons learned as well as the broader regulatory landscape and initiatives such as Breakthrough Devices, Digital Health, and Real World Evidence.

Melissa Torres

Associate Director for International Affairs, Center for Devices and Radiological Health
U.S. Food and Drug Administration
Tracey-Duffy

Tracey Duffy

First Assistant Secretary
Department of Health

How Advocacy can deliver for your MedTech Business

Day 3
09:45-10:30
Hear from MedTech leaders on how Advocacy and Government Relations can provide rewards for your business. The panel comprises a cross-section of Australia's MedTech leaders from large, medium and small companies in an interactive discussion on their tips and traps.
Sue-Martin

Sue Martin

Managing Director, Australia & New Zealand & MTAA Vice Chair
Johnson & Johnson
steven flynn

Steven Flynn

VP & General Manager - Australia and New Zealand & MTAA Vice Chair
Baxter International
Cortiula, Rebecca small

Rebecca Cortiula

Senior Managing Director Australasia & MTAA Board Director
Varian Medical
Brett

Brett Spence

Managing Director
Prism Surgical
Nick CAmpbell

Nick Campbell

Chairman
Nexus APAC

Morning Tea Break
10:30-11:00

Interview with LinkedIn

Day 3
11:00-11:45
Hear directly from LinkedIn on how medtech sales and marketing people can use LinkedIn to build their own online profile, advance their careers, and generate sales leads.
Tim Grogan

Tim Grogan

ANZ Sales Head and Key Accounts Enterprise Manager, APAC
LinkedIn
Joanne

Joanna Stevens

Head of Communications and Public Affairs
Johnson & Johnson

Building a Cyber Community to Protect Healthcare

Day 3
11:45-12:30
Hear from cyber security experts on the importance of protecting healthcare through a cyber community and why cyber security should be viewed as a benefit rather than just a cost.
Angela Coble

Angela Coble

CIO, Director Business Technology
Johnson & Johnson
Paul Davies

Paul Davies

Director for Government Affairs, Australia/New Zealand
Abbott Medical
Libby Day

Libby Day

Chief Executive Officer
Australia Medic Alert Foundation (A3C)
rob-grenfell

Dr Rob Grenfell

Health Director, Health & Biosecurity
CSIRO

Navigating the Journey of Product Commercialisation

Day 3 | 11:45-12:30
Understanding and translating varied stakeholder inputs and interests is an important activity at a very early stage in your medical technology development and commercialisation journey. This panel will offer perspectives and examples on how getting a detailed vision of your business model, and how engaging with regulatory authorities early can help navigate a complex commercialisation process. The session will also discuss how a country’s process for regulatory and reimbursement approvals can be an important determinant in deciding where to make investments in R&D and manufacturing capability.
George

George Sidis

Managing Director
IDE Group
Tara

Tara Croft

Chief Executive Officer
Baymatob
James Doyle Photo

James Doyle

Senior Director Commercial, Public Affairs & Spine
Stryker

Lunch Session: Developing Supportive Leadership for Mental Health

Day 3
12:30-13:30
Understand and discuss the essential leadership traits necessary to navigate mental health challenges in the workplace. It would be highly engaging content, but also practical in nature.
Adrianna Loveday Headshot

Adrianna Loveday

Psychologist & Founder
Kairos
Catherine

Catherine Wood

Senior HR Manager, Talent Management & Development, ANZ
Medtronic
Cortiula, Rebecca small

Rebecca Cortiula

Senior Managing Director Australasia & MTAA Board Director
Varian Medical
LizCarnabuci_Square FINAL

Liz Carnabuci

Vice President and Managing Director ANZ & MTAA Board Director
Medtronic

Wrap Up

Day 3
13:30-13:40
Maurice

Maurice Ben-Mayor

President & MTAA Chairman
Stryker South Pacific

Australian MedTech Industry Awards

Day 3
13:40-14:40
The Australian MedTech Industry Awards were set up by MTAA to recognise outstanding individuals and organisations in the MedTech industry. The Industry Awards are highly regarded within the medical technology sector are open to both MTAA members and non-members who have made a significant contribution to the industry.
Asset 15
Asset 16
Webinar-image

Three day broadcast

Watch the event live or on-demand

The MedTech21 conference will be completely virtual. Attendees will be able to ask questions, interact with presenters and more, all from the comfort of their home or office.

The new streaming service will give attendees the ability to watch any session at any time. 

Shopping Basket
We will notify you when registrations are open
We respect your privacy.
Favicon

Contact MTAA

Fill in the details below

We respect your privacy
We respect your privacy

This website uses cookies to ensure you get the best experience on our website.

Thank you for your enquiry.

MTAA will be in contact with you soon.